12:14 PM EST - BriaCell Therapeutics Corp : today reports updated survival data from its previously disclosed group of 12 patients (11 patients enrolled in 2021/2022) in the ongoing Phase II clinical trial evaluating Bria-IMT™ in combination with Incyte’s retifanlimab for the treatment of advanced metastatic breast cancer. 9 of 11 (82%) patients remain alive from 2021/2022 dosing, suggesting strong survival benefits. BriaCell Therapeutics Corp
shares T.BCT are trading -$0.45 at $9.55.
